 |
| |
| Aug-14-19 | Upgrade |
Atlantic Equities |
Neutral → Overweight |
$63 |
|
| May-28-19 | Initiated |
Goldman |
Buy |
|
|
| May-20-19 | Downgrade |
Argus |
Buy → Hold |
|
|
| May-03-19 | Upgrade |
Barclays |
Equal Weight → Overweight |
$53 → $55 |
|
| May-03-19 | Resumed |
JP Morgan |
Overweight |
$62 |
|
| Jan-15-19 | Upgrade |
Societe Generale |
Sell → Buy |
|
|
| Oct-22-18 | Downgrade |
Citigroup |
Buy → Neutral |
|
|
| Oct-09-18 | Resumed |
Guggenheim |
Neutral |
|
|
| Aug-08-18 | Upgrade |
Atlantic Equities |
Underweight → Neutral |
|
|
| Apr-17-18 | Downgrade |
Morgan Stanley |
Overweight → Equal-Weight |
|
|
| Apr-12-18 | Reiterated |
Citigroup |
Buy |
$78 → $70 |
|
| Mar-20-18 | Reiterated |
JP Morgan |
Overweight |
$70 → $75 |
|
| Feb-15-18 | Upgrade |
Morgan Stanley |
Equal-Weight → Overweight |
|
|
| Oct-30-17 | Upgrade |
SunTrust |
Hold → Buy |
|
|
| Oct-16-17 | Downgrade |
Jefferies |
Buy → Hold |
|
|
| Sep-12-17 | Downgrade |
Hilliard Lyons |
Long-term Buy → Neutral |
|
|
| Dec-19-16 | Upgrade |
Jefferies |
Hold → Buy |
|
|
| Oct-28-16 | Reiterated |
Deutsche Bank |
Hold |
$59 → $52 |
|
| Sep-09-16 | Reiterated |
Barclays |
Equal Weight |
$75 → $65 |
|
| Aug-11-16 | Downgrade |
Berenberg |
Buy → Hold |
|
|
|
|
| Sep-20-19 04:52PM | Mike Quigley has personal motivation leading oncology at Bristol-Myers Squibb American City Business Journals |
| 04:29PM | 5 Safe Bets for a Rocky Market Zacks |
| 11:00AM | iShares Reveals New Corporate Bond ETF IBDU ETF Database |
| 10:49AM | Zacks Value Trader Highlights: Exact Sciences, Edwards Lifesciences, Bristol Myers-Squibb, Occidental Petroleum and Exxon Mobil Zacks |
| 08:31AM | 3 Big Biotech Stocks Worth Adding to Your Portfolio Now Zacks |
| 06:59AM | Bristol-Myers Squibb to Hold Investor Webcast to Discuss ESMO Highlights Business Wire |
| Sep-19-19 01:29PM | Does Bristol-Myers Squibb Company's (NYSE:BMY) CEO Pay Reflect Performance? Simply Wall St. |
| 11:15AM | 11 Most Aggressively Shorted Stocks Benzinga |
| 11:05AM | Stock Investors: Do You Need a Late Cycle Plan? Zacks |
| 08:09AM | Bristol-Myers Squibb Is Set to Emerge From a Basing Pattern TheStreet.com |
| 06:59AM | Bristol-Myers Squibb Research at ESMO Demonstrates Breadth of Oncology Development Program and Focus on Improving Overall Survival Across Multiple Cancers Business Wire |
| Sep-18-19 10:04AM | Roche's Gazyva Now a Breakthrough Therapy for Lupus Nephritis Zacks |
| Sep-17-19 05:45PM | Bristol-Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know Zacks |
| 11:05AM | Novartis Announces New Data on Spondylitis Drug Cosentyx Zacks |
| Sep-16-19 10:43AM | AstraZeneca's Farxiga Gets Fast Track Tag for Heart Failure Zacks |
| Sep-13-19 10:30AM | Celgene's (CELG) Leukemia Candidate Meets Endpoints in Study Zacks |
| 09:36AM | Renal Cell Carcinoma Space in Focus: Some Key Developments Zacks |
| 04:47AM | Roche Reports Positive Data on Tecentriq & NMOSD Drug (Revised) Zacks |
| Sep-12-19 07:25PM | Seth Klarman's Favorite Health Care Stocks GuruFocus.com |
| 05:46PM | Gilead Tops List of Most Innovative Drug Companies GuruFocus.com |
| 01:36PM | 2 Large-Cap Companies Declare Dividends GuruFocus.com |
| 10:02AM | Horizon (HZNP) Up 36.7% YTD: Pipeline Development in Focus Zacks |
| 09:20AM | Zacks Market Edge Highlights: UnitedHealth, Centene, MasTec, Bank of America and Bristol-Myers Squibb Zacks |
| 09:09AM | Roche (RHHBY) Reports Positive Data on Tecentriq & MS Drug Zacks |
| 07:59AM | Top Ranked Income Stocks to Buy for September 12th Zacks |
| 07:43AM | Wall Street Bulls Roaring Despite Slowdown Fears: 5 Top Picks Zacks |
| 06:59AM | Bristol-Myers Squibb to Announce Results for Third Quarter 2019 on October 31, 2019 Business Wire |
| Sep-11-19 05:45PM | Bristol-Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know Zacks |
| 05:39PM | Bristol-Myers Squibb Board Announces Election of Three New Directors Business Wire |
| 04:16PM | BristolMyers Squibb Announces Dividend Business Wire |
| 12:05PM | Could the Trade War be Bullish for Stocks? Zacks |
| 11:40AM | AVEO Surges on Favorable Updated OS Results on RCC Drug Zacks |
| 11:13AM | Bristol-Myers' (BMY) Opdivo Shows Long-Term Survival Benefit Zacks |
| 09:32AM | 4 Big Drugmakers Boasting Impressive Oncology Pipelines Zacks |
| Sep-10-19 01:38PM | 7 Cheap Stocks to Buy in a Pricey Market Kiplinger |
| 11:18AM | Aveo CEO says new data eases concerns about troubled kidney cancer drug American City Business Journals |
| 05:30AM | Bristol-Myers Squibb Announces Pooled Five-Year Survival Results for Opdivo (nivolumab) in Previously-Treated Advanced Non-Small Cell Lung Cancer Patients Business Wire |
| Sep-09-19 11:33AM | The Zacks Analyst Blog Highlights: Allergan, Merck, Roche, J&J and Bristol-Myers Zacks |
| 09:15AM | Why Bristol-Myers Squibb (BMY) is a Great Dividend Stock Right Now Zacks |
| 07:25AM | Top Ranked Income Stocks to Buy for September 9th Zacks |
| Sep-08-19 09:00AM | Better Buy: Amgen vs. Celgene Motley Fool |
| Sep-07-19 12:30PM | Is Bristol-Myers Squibb a Buy? Motley Fool |
| Sep-06-19 03:06PM | Why Amgen's Spending Billions to Buy This 1 Drug; Plus Heart Disease Has a New Enemy Motley Fool |
| 11:36AM | Pharma Stock Roundup: AGN's Opioid Settlement, Line Extension Nod in EU for MRK, JNJ Drugs Zacks |
| 11:29AM | Bristol-Myers' (BMY) Opdivo Falls Flat in Brain Tumor Study Zacks |
| 08:00AM | BMY Stock Plus Celgene Will Be A Top 5 Pharma But Should You Buy It? Investor's Business Daily |
| Sep-05-19 04:51PM | 3 Special Situations Gurus Are Buying GuruFocus.com |
| 10:24AM | Infinity Initiates 2 Studies for Lead Candidate IPI-549 Zacks |
| 08:58AM | The Zacks Analyst Blog Highlights: Allegiant, Bristol-Myers, NewMarket, North American Construction and TiVo Zacks |
| 08:12AM | The Daily Biotech Pulse: Cheery Results For Sage's Depression Drug, UniQure Offering, Axsome Aces Study Of Headache Drug Benzinga |
| 07:24AM | Bristol-Myers cancer drug Opdivo fails to meet a primary endpoint in phase 3 trial MarketWatch |
| 07:09AM | Bristol-Myers' Opdivo fails to meet goal of brain tumor study Reuters |
| 07:01AM | Novartis signs $840M pact with IFM Due amid fallout from AveXis deal American City Business Journals |
| 05:10AM | Bristol-Myers Stock Slips After Brain-Cancer-Drug Disappointment TheStreet.com |
| Sep-04-19 03:14PM | Here's Why Nektar Therapeutics Plummeted 38% in August Motley Fool |
| 09:39AM | Roche Extends Offer to Acquire Spark Therapeutics Yet Again Zacks |
| 09:22AM | 5 Strong Buy Ultra-Safe Stocks for an Uncertain September Zacks |
| 09:19AM | The Zacks Analyst Blog Highlights: TransDigm, Keysight, Bristol-Myers Squibb, NRG and Arconic Zacks |
| 07:00AM | More Than 100 Bristol-Myers Squibb Employees Embark on Coast 2 Coast 4 Cancer Ride to Help Advance Groundbreaking Cancer Research Business Wire |
| Sep-03-19 05:46PM | Top-Performing Biotech ETFs YTD Zacks |
| 09:21AM | The Zacks Analyst Blog Highlights: J&J, Eli Lilly, Bristol-Myers, Roche and AbbVie Zacks |
| 08:00AM | Looking For Growth? Take A Look At These Biotechnology Stocks Investor's Business Daily |
| 07:02AM | 5 Cancer-Fighting Stocks to Add to Your Portfolio Zacks |
| Sep-02-19 07:14AM | 5 Top S&P 500 Stocks Soaring Despite Worst August Since 2015 Zacks |
| Aug-30-19 05:45PM | Bristol-Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know Zacks |
| 11:33AM | The Zacks Analyst Blog Highlights: Bristol-Myers Squibb, Alamos Gold, Americold Realty Trust, TransDigm and frontdoor Zacks |
| 11:30AM | The Zacks Analyst Blog Highlights: Bristol-Myers Squibb, ONEOK, Verizon Communications, Principal Financial and Omnicom Zacks |
| 10:11AM | Pharma Stock Roundup: JNJ's Opioid Lawsuit, Regulatory Nod for LLY, BMY, RHHBY Drugs Zacks |
| 09:49AM | Why this biotech's new-school opioid is on hold with the FDA American City Business Journals |
| Aug-29-19 09:15AM | Dow Jumps 1% Despite Yield Curve Worries Zacks |
| 08:15AM | 5 Top Momentum Stocks in August Despite Market Mayhem Zacks |
| 07:33AM | Will Treasury Yield Inversion Benefit Stocks? 5 Top Picks Zacks |
| Aug-28-19 06:55PM | What Investors Need to Know About the Celgene, Amgen & Bristol-Myers Deals Zacks |
| 05:19PM | 6 Seth Klarman Stocks With Low Price-Earnings Ratios GuruFocus.com |
| 01:56PM | Bristol-Myers Squibb Gains Europe's Approval for Empliciti GuruFocus.com |
| 10:54AM | Celgene Strikes Cancer Immunotherapy Deal With Immatics For Up To $1.59B Benzinga |
| 10:38AM | The Zacks Analyst Blog Highlights: Bristol-Myers Squibb Company, Celgene, Exact Sciences, Pfizer and Guardant Health Zacks |
| 10:15AM | Bristol-Myers' Empliciti Gets EMA Nod for Label Expansion Zacks |
| 10:00AM | 10 Best Dividend Stocks to Buy for the Rest of 2019 and Beyond InvestorPlace |
| 07:31AM | The Daily Biotech Pulse: EC Nod For Bristol-Myers Squibb, Kyowa Kirin's Parkinson's Add-On Therapy Approved Benzinga |
| 06:28AM | Alexion Wins EC Nod for Soliris in Nervous System Disorder Zacks |
| 05:56AM | Those Who Purchased Bristol-Myers Squibb (NYSE:BMY) Shares A Year Ago Have A 20% Loss To Show For It Simply Wall St. |
| Aug-27-19 04:16PM | European Commission Approves Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone (EPd) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma Business Wire |
| 11:01AM | 4 Biotech Stocks to Buy That Are on the Move InvestorPlace |
| 10:55AM | Amgen to Buy Celgene's Otezla for $13.4B: Is it a Good Buy? Zacks |
| 10:05AM | Amgen to Buy Celgene's Otezla: 5 ETF Drugs Zacks |
| 09:24AM | 3 Cancer Treatment Stocks to Enrich Your Portfolio Zacks |
| 08:58AM | Alexion (ALXN) Down 3.2% After Amgen Buys Otezla From Celgene Zacks |
| 08:05AM | Bristol-Myers Announces Sale of Celgene's Otezla to Amgen Zacks |
| 08:00AM | Presage Announces Collaboration with Bristol-Myers Squibb for Phase O Studies of Novel Cancer Agents Utilizing CIVO Technology PR Newswire |
| Aug-26-19 10:04PM | US Stock Market Overview – Stock Surge as Trump Flip Flops Lifting Dow Industrials FX Empire |
| 05:06PM | What Happened in the Stock Market Today Motley Fool |
| 04:34PM | Stock Market Today: Biotech in Focus, Trade Talks Steady Stocks InvestorPlace |
| 03:32PM | 5 Top Stock Trades for Tuesday: NFLX, AMGN, ACB, BMY InvestorPlace |
| 01:53PM | Celgene News: CELG Stock Jumps on Sale of Otezla to Amgen InvestorPlace |
| 01:25PM | Hedge Funds' Most-Bought Stocks Last Quarter GuruFocus.com |
| 01:21PM | Amgen's Proposed $13.4B Acquisition Of Celgene's Otezla: What You Need To Know Benzinga |
| 10:57AM | Amgen Will Buy Celgene Drug in $13.4 Billion Antitrust Sale Bloomberg |
| 09:14AM | Bristol-Meyers Deal for Celgene Moves Ahead After the Sale of Psoriasis Drug Barrons.com |
| 06:46AM | Amgen to buy Celgene psoriasis drug Otezla for $13.4 billion Reuters |
|
|
|
|
| Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis. It also provides Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; and Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B. In addition, the company offers Reyataz, a protease inhibitor for the treatment of human immunodeficiency virus (HIV) and Evotaz; Sustiva franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV; and Daklinza NS5A replication complex inhibitor, Sunvepra NS3 protease inhibitor, and Beclabuvir NS5B inhibitor. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. It has collaboration agreements with Nektar Therapeutics; Janssen Pharmaceuticals, Inc.; Biocartis Group NV.; FameWave Ltd.; Novartis; and Presage Biosciences. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Santiago Karen Murphy | Controller | Sep 01 | Option Exercise | 0.00 | 641 | 0 | 3,707 | Sep 04 05:17 PM | | BERTOLINI ROBERT J | Director | Jul 31 | Buy | 44.72 | 11,000 | 491,920 | 11,397 | Aug 01 05:06 PM | | Samuels Theodore R. II | Director | May 16 | Buy | 47.29 | 5,000 | 236,440 | 27,000 | May 20 04:36 PM | | Santiago Karen Murphy | Controller | May 16 | Sale | 47.56 | 3,065 | 145,771 | 3,066 | May 20 04:37 PM | | Caforio Giovanni | Chairman and CEO | May 05 | Option Exercise | 0.00 | 8,040 | 0 | 373,239 | May 06 04:40 PM | | Lynch Thomas J. Jr. | EVP & Chief Scientific Officer | Apr 03 | Option Exercise | 0.00 | 11,594 | 0 | 25,816 | Apr 05 04:32 PM | | Elicker John E | SVP, Public Affairs & IR | Mar 10 | Option Exercise | 0.00 | 14,180 | 0 | 92,626 | Mar 13 07:42 AM | | BOERNER CHRISTOPHER S. | EVP, Chief Commercial Officer | Mar 10 | Option Exercise | 0.00 | 15,707 | 0 | 14,501 | Mar 13 07:41 AM | | Dubow Adam | Chief Compliance & Ethics Offi | Mar 10 | Option Exercise | 0.00 | 3,735 | 0 | 18,240 | Mar 13 07:41 AM | | Caforio Giovanni | Chairman and CEO | Mar 10 | Option Exercise | 0.00 | 173,419 | 0 | 422,683 | Mar 13 07:40 AM | | Bancroft Charles A | EVP & Chief Financial Officer | Mar 10 | Option Exercise | 0.00 | 62,255 | 0 | 411,547 | Mar 13 07:39 AM | | Biondi Paul | SVP, Head of Strategy & BD | Mar 10 | Option Exercise | 0.00 | 8,619 | 0 | 7,860 | Mar 13 07:39 AM | | von Autenried Paul | SVP, Enterp. Services & CIO | Mar 10 | Option Exercise | 0.00 | 19,925 | 0 | 141,077 | Mar 13 07:38 AM | | Schmukler Louis S | Pres., Global Mfg. & Supply | Mar 10 | Option Exercise | 0.00 | 26,568 | 0 | 63,652 | Mar 13 07:37 AM | | Lynch Thomas J. Jr. | EVP & Chief Scientific Officer | Mar 10 | Option Exercise | 0.00 | 5,864 | 0 | 21,343 | Mar 13 07:36 AM | | Santiago Karen Murphy | Controller | Mar 10 | Option Exercise | 0.00 | 3,825 | 0 | 6,850 | Mar 13 07:37 AM | | LEUNG SANDRA | EVP, General Counsel | Mar 10 | Option Exercise | 0.00 | 45,170 | 0 | 558,854 | Mar 13 07:35 AM | | JUDGE ANN POWELL | SVP, Global Human Resources | Mar 10 | Option Exercise | 0.00 | 25,577 | 0 | 81,508 | Mar 13 07:34 AM | | Bancroft Charles A | EVP & Chief Financial Officer | Feb 28 | Option Exercise | 17.51 | 52,884 | 925,999 | 392,690 | Mar 04 04:42 PM | | LEUNG SANDRA | EVP, General Counsel | Feb 28 | Option Exercise | 17.51 | 169,893 | 2,974,826 | 634,478 | Mar 04 04:42 PM | | BOERNER CHRISTOPHER S. | EVP, Chief Commercial Officer | Feb 02 | Option Exercise | 0.00 | 4,465 | 0 | 4,465 | Feb 05 04:53 PM | | Bancroft Charles A | EVP & Chief Financial Officer | Dec 02 | Option Exercise | 0.00 | 6,401 | 0 | 206,117 | Dec 04 04:31 PM | | Biondi Paul | SVP, Head of Strategy & BD | Oct 02 | Option Exercise | 0.00 | 592 | 0 | 592 | Oct 04 04:56 PM |
|
|
|
|
|
|
